1-3 of 3
Sameera R. Wijayawardana
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Helena A. Yu, Luis G. Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 992–1002.
https://doi.org/10.1158/1078-0432.CCR-20-1690
Published: 15 February 2021
View article titled, Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <em>EGFR</em>-mutant Non–small Cell Lung Cancer
Open the PDF for Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <em>EGFR</em>-mutant Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

James J. Harding, Andrew X. Zhu, Todd M. Bauer, Toni K. Choueiri, Alexander Drilon, Martin H. Voss, Charles S. Fuchs, Ghassan K. Abou-Alfa, Sameera R. Wijayawardana, Xuejing Aimee Wang, Brian A. Moser, Arantxa Uruñuela, Volker Wacheck, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5202–5211.
https://doi.org/10.1158/1078-0432.CCR-18-4010
Published: 03 September 2019
View article titled, A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Open the PDF for A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, Palaniappan Kulanthaivel, Celine Pitou, Lynette B. Mulle, Daphne L. Farrington, Edward M. Chan, Matthew P. Goetz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (5): 1095–1102.
https://doi.org/10.1158/1078-0432.CCR-15-1718
Published: 29 February 2016
View article titled, A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer in another window
Includes: Supplementary data